secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001628280-25-052771
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance
--------------------------------------------------------------------------------

- Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).
- Cardiovascular revenue $3.44B (+9.3% organic); Cardiac Ablation Solutions up 71% on PFA portfolio.
- Raises FY26 organic revenue growth guidance to ~5.5% (from ~5.0%); non-GAAP EPS guidance to $5.62-$5.66.
- Received FDA approval for Altaviva device for urge UI; CMS NCD for Symplicity hypertension procedure.
- Diabetes revenue $757M (+7.1% organic); Hugo robotic surgery study met safety and effectiveness endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000162828025052771/0001628280-25-052771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000162828025052771/mdt-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer